Speakers
Rebecca Noel, DrPH, MPH
Executive Director, Benefit-Risk Assessment, Eli Lilly, United States
Rebecca (Becky) Noel is currently the Global Leader for Benefit-Risk Assessment at Eli Lilly. Since joining Lilly, Becky has been extensively involved in leading the development of systematic approaches to benefit-risk assessment, both internally at Lilly and externally via the PhRMA Benefit-Risk Action Team (BRAT), the Innovative Medicines Initiative PROTECT project, the International Conference on Harmonization, and via multiple other forums.
Louis Garrison, PhD
Professor, Pharmaceutical Outcomes Research and Policy Program, University of Washington, United States
Dr. Garrison is Professor in the Pharmaceutical Outcomes Research and Policy Program in the School of Pharmacy, and Adjunct Professor in the Departments of Global Health and Health Services at the University of Washington, where he joined the faculty in 2004. He also co-directs the Global Medicines Program in Global Health. From 2007-2009, Dr. Garrison served on the ISPOR Board of Directors. He co-chaired two ISPOR Good Practice Task Forces—on Real-World Data and on Performance-Based Risk-Sharing Arrangements, and he chaired the ISPOR Health Science Policy Council from 2012 to 2015. He is faculty advisor for the UW ISPOR Student Chapter, and is ISPOR President-elect for 2016-17.
James Cross, PhD, MS
Head of Regulatory Affairs, Kodiak Sciences, United States
Have an account?